Stellate Ganglion Block with Lidocaine for the Treatment of COVID-19-Induced Parosmia

PHASE3RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

December 24, 2025

Study Completion Date

May 15, 2026

Conditions
Parosmia
Interventions
PROCEDURE

Stellate Ganglion Block

All SGBs will be performed by a board-certified anesthesiologist and pain management specialist with extensive experience performing SGBs. The laterality of the SGB will be randomized between the left and right sides of the neck. Participants will be asked to abstain from eating and drinking for 8 hours prior to the SGB. Using ultrasound guidance, the transverse process of the C6 vertebra is identified. Color-doppler is used to identify blood vessels. A 27-gauge needle is used to anesthetize the superficial skin with 1% lidocaine. Then, a 21-gauge ultrasound needle is advanced using an in-plane technique from lateral to medial with careful avoidance of neurovascular structures. After negative aspiration, 8 mL of 1% Lidocaine is deposited beneath the prevertebral fascia and above the Longus coli muscle into the stellate ganglion.

OTHER

Placebo

The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine

Trial Locations (1)

N6A 4V2

RECRUITING

St. Joseph's Hospital London, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER